{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T19:44:11Z","timestamp":1788983051969,"version":"build-2803163510"},"reference-count":97,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100017804","name":"City of Hope","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017804","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.hoc.2025.05.010","type":"journal-article","created":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T16:05:33Z","timestamp":1751990733000},"page":"981-995","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Immunotherapy in Chronic Lymphocytic Leukemia"],"prefix":"10.1016","volume":"39","author":[{"given":"Brian","family":"Sworder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya","family":"Siddiqi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hoc.2025.05.010_bib1","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_432204","article-title":"Charting the course: sequencing immunotherapy for multiple myeloma","volume":"44","author":"Mohan","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.hoc.2025.05.010_bib2","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1056\/NEJMoa2405888","article-title":"Nivolumab+AVD in advanced-stage classic Hodgkin\u2019s Lymphoma","volume":"391","author":"Herrera","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hoc.2025.05.010_bib3","article-title":"Relapsed\/refractory CLL: the role of allo-SCT, CAR-T, and T-cell engagers","volume":"474-481","author":"Kater","year":"2024","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.hoc.2025.05.010_bib4","doi-asserted-by":"crossref","first-page":"7757","DOI":"10.1158\/1078-0432.CCR-05-0941","article-title":"Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q- and 17p-)","volume":"11","author":"Caballero","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hoc.2025.05.010_bib5","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1182\/blood-2003-12-4321","article-title":"Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCR","volume":"104","author":"Ritgen","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2025.05.010_bib6","doi-asserted-by":"crossref","first-page":"4113","DOI":"10.1182\/bloodadvances.2020002184","article-title":"Allogeneic hematopoietic cell transplantation after prior targeted therapy for high-risk chronic lymphocytic leukemia","volume":"4","author":"Kim","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.hoc.2025.05.010_bib7","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1182\/blood-2010-03-275420","article-title":"Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial","volume":"116","author":"Dreger","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2025.05.010_bib8","doi-asserted-by":"crossref","first-page":"3819","DOI":"10.1200\/JCO.2005.04.569","article-title":"Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia","volume":"23","author":"Sorror","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2025.05.010_bib9","doi-asserted-by":"crossref","first-page":"4912","DOI":"10.1200\/JCO.2007.15.4757","article-title":"Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning","volume":"26","author":"Sorror","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2025.05.010_bib10","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1182\/blood-2017-04-775841","article-title":"Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSG CLL3X trial","volume":"130","author":"Kramer","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2025.05.010_bib11","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1182\/blood-2010-04-001230","article-title":"The clinical application of monoclonal antibodies in chronic lymphocytic leukemia","volume":"116","author":"Jaglowski","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2025.05.010_bib12","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/256495a0","article-title":"Continuous cultures of fused cells secreting antibody of predefined specificity","volume":"256","author":"Kohler","year":"1975","journal-title":"Nature"},{"key":"10.1016\/j.hoc.2025.05.010_bib13","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1056\/NEJM198203043060906","article-title":"Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody","volume":"306","author":"Miller","year":"1982","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hoc.2025.05.010_bib14","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1172\/JCI110005","article-title":"A unique cell surface antigen identifying lymphoid malignancies of B cell origin","volume":"67","author":"Nadler","year":"1981","journal-title":"J Clin Investig"},{"issue":"Suppl 2","key":"10.1016\/j.hoc.2025.05.010_bib15","first-page":"S1","article-title":"Mechanism of action of rituximab","volume":"12","author":"Maloney","year":"2001","journal-title":"Anti Cancer Drugs"},{"key":"10.1016\/j.hoc.2025.05.010_bib16","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1023\/A:1008416911099","article-title":"Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin\u2019s lymphoma","volume":"9","author":"Berinstein","year":"1998","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2025.05.010_bib17","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1182\/blood.V98.5.1326","article-title":"Rituximab therapy of patients with B-cell chronic lymphocytic leukemia","volume":"98","author":"Huhn","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2025.05.010_bib18","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1034\/j.1600-0609.2002.02786.x","article-title":"Standard-dose anti-CD20 antibody rituximab has efficacy in chronic lymphocytic leukaemia: results from a Nordic multicentre study","volume":"69","author":"Itala","year":"2002","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.hoc.2025.05.010_bib19","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1053\/j.seminhematol.2010.01.005","article-title":"Rituximab in chronic lymphocytic leukemia","volume":"47","author":"Jaglowski","year":"2010","journal-title":"Semin Hematol"},{"key":"10.1016\/j.hoc.2025.05.010_bib20","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.hoc.2025.05.010_bib21","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1200\/JCO.2009.26.4556","article-title":"Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia","volume":"28","author":"Robak","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2025.05.010_bib22","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1182\/blood-2010-09-305847","article-title":"Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I\/II distinction of CD20 antibodies","volume":"118","author":"Niederfellner","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2025.05.010_bib23","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1182\/blood-2009-06-225979","article-title":"Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity","volume":"115","author":"Mossner","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2025.05.010_bib24","doi-asserted-by":"crossref","first-page":"3762","DOI":"10.4049\/jimmunol.1000303","article-title":"Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab","volume":"186","author":"Bologna","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.hoc.2025.05.010_bib25","doi-asserted-by":"crossref","first-page":"3482","DOI":"10.1182\/blood-2013-05-504043","article-title":"Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab","volume":"122","author":"Golay","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2025.05.010_bib26","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.hoc.2025.05.010_bib97","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1056\/NEJMoa2213093","article-title":"First-line venetoclax combinations in chronic lymphocytic leukemia","volume":"388","author":"Eichhorst","year":"2023","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.hoc.2025.05.010_bib98","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S1470-2045(24)00196-7","article-title":"First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA\/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial","volume":"25","author":"F\u00fcrstenau","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.hoc.2025.05.010_bib29","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.hoc.2025.05.010_bib30","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2024024476","article-title":"Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN","author":"Sharman","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2025.05.010_bib31","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1056\/NEJMoa2409804","article-title":"Fixed-duration acalabrutinib combinations in untreated chronic lymphocytic leukemia","volume":"392","author":"Brown","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hoc.2025.05.010_bib32","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1200\/JCO-24-02503","article-title":"Phase II study of acalabrutinib, venetoclax, and obinutuzumab in a treatment-Na\u00efve chronic lymphocytic leukemia population enriched for high-risk disease","volume":"43","author":"Davids","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2025.05.010_bib27","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/bjh.19521","article-title":"Real-world experience of axicabtagene ciloleucel, a CD19-directed CAR T-cell therapy, in the second-line treatment of early relapsed or primary refractory large B-cell lymphoma","volume":"205","author":"Othman","year":"2024","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2025.05.010_bib33","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hoc.2025.05.010_bib34","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1200\/JCO.23.02214","article-title":"Lisocabtagene maraleucel in relapsed\/refractory mantle cell lymphoma: primary analysis of the mantle cell lymphoma cohort from TRANSCEND NHL 001, a phase I multicenter seamless design study","volume":"42","author":"Wang","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2025.05.010_bib35","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-Cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hoc.2025.05.010_bib36","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1084\/jem.181.5.1653","article-title":"Signals through T cell receptor-zeta chain alone are insufficient to prime resting T lymphocytes","volume":"181","author":"Brocker","year":"1995","journal-title":"J Exp Med"},{"key":"10.1016\/j.hoc.2025.05.010_bib37","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1002\/eji.1830230705","article-title":"New simplified molecular design for functional T cell receptor","volume":"23","author":"Brocker","year":"1993","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.hoc.2025.05.010_bib38","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1517\/14712598.2015.1046430","article-title":"TRUCKs: the fourth generation of CARs","volume":"15","author":"Chmielewski","year":"2015","journal-title":"Expet Opin Biol Ther"},{"key":"10.1016\/j.hoc.2025.05.010_bib39","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/nbt0102-70","article-title":"Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta\/CD28 receptor","volume":"20","author":"Maher","year":"2002","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.hoc.2025.05.010_bib40","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.hoc.2025.05.010_bib41","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-Cell Lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hoc.2025.05.010_bib42","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1182\/blood-2023-179529","article-title":"Lisocabtagene maraleucel (liso-cel) in R\/R CLL\/SLL: 24-month median follow-up of TRANSCEND CLL 004","volume":"142","author":"Siddiqi","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2025.05.010_bib43","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hoc.2025.05.010_bib44","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","article-title":"Decade-long leukaemia remissions with persistence of CD4(+) CAR T cells","volume":"602","author":"Melenhorst","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.hoc.2025.05.010_bib45","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1200\/JCO.2017.72.8519","article-title":"Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified t cells after failure of ibrutinib","volume":"35","author":"Turtle","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2025.05.010_bib46","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1200\/JCO.20.01467","article-title":"Long-term follow-up of anti-CD19 chimeric antigen receptor T-cell therapy","volume":"38","author":"Cappell","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2025.05.010_bib47","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2024027460","article-title":"ZUMA-8: a phase 1 study of brexucabtagene autoleucel in patients with relapsed\/refractory chronic lymphocytic leukemia","author":"Davids","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2025.05.010_bib48","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0140-6736(23)01052-8","article-title":"Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study","volume":"402","author":"Siddiqi","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.hoc.2025.05.010_bib49","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1053\/j.seminhematol.2024.01.001","article-title":"Transforming CLL management with immunotherapy: investigating the potential of CAR T-cells and bispecific antibodies","volume":"61","author":"Borogovac","year":"2024","journal-title":"Semin Hematol"},{"key":"10.1016\/j.hoc.2025.05.010_bib50","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000988","article-title":"CAR-modified cellular therapies in chronic lymphocytic leukemia: is the uphill road getting less steep?","volume":"7","author":"Vitale","year":"2023","journal-title":"Hemasphere"},{"key":"10.1016\/j.hoc.2025.05.010_bib51","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ccell.2022.12.005","article-title":"Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas","volume":"41","author":"Sworder","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.hoc.2025.05.010_bib52","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1038\/s41591-020-1061-7","article-title":"Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas","volume":"26","author":"Deng","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.hoc.2025.05.010_bib53","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/s41591-023-02754-1","article-title":"Impact of tumor microenvironment on efficacy of anti-CD19 CAR T cell therapy or chemotherapy and transplant in large B cell lymphoma","volume":"30","author":"Locke","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.hoc.2025.05.010_bib54","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/s41577-019-0221-9","article-title":"Defining \u2018T cell exhaustion\u2019","volume":"19","author":"Blank","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.hoc.2025.05.010_bib55","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s11899-011-0106-x","article-title":"Immune reconstitution in chronic lymphocytic leukemia","volume":"7","author":"Riches","year":"2012","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.hoc.2025.05.010_bib56","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.2174\/138161212801227023","article-title":"Immune dysfunction in chronic lymphocytic leukemia: the role for immunotherapy","volume":"18","author":"Riches","year":"2012","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.hoc.2025.05.010_bib57","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.leukres.2010.08.010","article-title":"Regulatory T-cell number is increased in chronic lymphocytic leukemia patients and correlates with progressive disease","volume":"35","author":"D\u2019Arena","year":"2011","journal-title":"Leuk Res"},{"key":"10.1016\/j.hoc.2025.05.010_bib58","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1365-2567.2010.03308.x","article-title":"T regulatory cells control T-cell proliferation partly by the release of soluble CD25 in patients with B-cell malignancies","volume":"131","author":"Lindqvist","year":"2010","journal-title":"Immunology"},{"key":"10.1016\/j.hoc.2025.05.010_bib59","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1084\/jem.176.5.1319","article-title":"Interleukin 4 protects chronic lymphocytic leukemic B cells from death by apoptosis and upregulates Bcl-2 expression","volume":"176","author":"Dancescu","year":"1992","journal-title":"J Exp Med"},{"key":"10.1016\/j.hoc.2025.05.010_bib60","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0145-2126(97)00152-5","article-title":"Peripheral blood lymphocyte subset shifts in patients with untreated hematological tumors: evidence for systemic activation of the T cell compartment","volume":"22","author":"Van den Hove","year":"1998","journal-title":"Leuk Res"},{"key":"10.1016\/j.hoc.2025.05.010_bib61","first-page":"157","article-title":"Imbalance of T cell subpopulations in patients with chronic lymphocytic leukaemia of the B cell type","volume":"49","author":"Herrmann","year":"1982","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.hoc.2025.05.010_bib62","first-page":"2427","article-title":"Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug","volume":"118","author":"Ramsay","year":"2008","journal-title":"J Clin Investig"},{"key":"10.1016\/j.hoc.2025.05.010_bib63","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1182\/blood-2017-06-786129","article-title":"Cellular kinetics of CTL019 in relapsed\/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia","volume":"130","author":"Mueller","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2025.05.010_bib64","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.hoc.2025.05.010_bib65","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.3389\/fimmu.2017.01956","article-title":"Differences in expansion potential of naive chimeric antigen receptor t cells from healthy donors and untreated chronic lymphocytic leukemia patients","volume":"8","author":"Hoffmann","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.hoc.2025.05.010_bib66","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.omto.2019.08.002","article-title":"Parallel comparison of 4-1BB or CD28 Co-stimulated CD19-targeted CAR-T cells for B cell non-Hodgkin\u2019s lymphoma","volume":"15","author":"Ying","year":"2019","journal-title":"Mol Ther Oncolytics"},{"key":"10.1016\/j.hoc.2025.05.010_bib67","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1182\/blood-2014-12-618025","article-title":"Exosomes released by chronic lymphocytic leukemia cells induce the transition of stromal cells into cancer-associated fibroblasts","volume":"126","author":"Paggetti","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2025.05.010_bib68","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1182\/blood.V96.8.2655","article-title":"Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1","volume":"96","author":"Burger","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2025.05.010_bib69","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1182\/blood-2013-12-546416","article-title":"CLL-cells induce IDOhi CD14+HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs","volume":"124","author":"Jitschin","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2025.05.010_bib70","doi-asserted-by":"crossref","first-page":"3905","DOI":"10.1182\/blood-2015-01-621474","article-title":"Tumor indoleamine 2,3-dioxygenase (Ido) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs","volume":"125","author":"Ninomiya","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2025.05.010_bib71","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/j.ymthe.2020.12.033","article-title":"Leukemic extracellular vesicles induce chimeric antigen receptor T cell dysfunction in chronic lymphocytic leukemia","volume":"29","author":"Cox","year":"2021","journal-title":"Mol Ther"},{"key":"10.1016\/j.hoc.2025.05.010_bib72","first-page":"A477","article-title":"449 Concurrent ibrutinib enhances T cell function in patients with chronic lymphocytic leukemia (CLL) treated with lisocabtagene maraleucel (liso-cel), a chimeric antigen receptor (CAR) T cell therapy","volume":"9","author":"Thorpe","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.hoc.2025.05.010_bib73","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1182\/blood-2024-200339","volume":"144","author":"Wierda","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2025.05.010_bib74","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1115940","article-title":"Lenalidomide enhances antitumor functions of chimeric antigen receptor modified T cells","volume":"5","author":"Otahal","year":"2016","journal-title":"OncoImmunology"},{"key":"10.1016\/j.hoc.2025.05.010_bib75","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1080\/10428194.2022.2043299","article-title":"Lenalidomide enhances CD23.CAR T cell therapy in chronic lymphocytic leukemia","volume":"63","author":"Tettamanti","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.hoc.2025.05.010_bib76","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1182\/blood-2015-01-622936","article-title":"PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia","volume":"126","author":"McClanahan","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2025.05.010_bib77","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1182\/blood-2017-02-765685","article-title":"Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL","volume":"129","author":"Ding","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2025.05.010_bib78","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.hoc.2025.05.010_bib79","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1158\/2643-3230.BCD-21-0177","article-title":"Clonal hematopoiesis is associated with increased risk of severe neurotoxicity in axicabtagene ciloleucel therapy of large b-cell lymphoma","volume":"3","author":"Saini","year":"2022","journal-title":"Blood Cancer Discov"},{"key":"10.1016\/j.hoc.2025.05.010_bib80","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1182\/blood-2016-04-712562","article-title":"High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia","volume":"128","author":"Cui","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2025.05.010_bib81","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2010-05-283309","article-title":"The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor","volume":"116","author":"Hudecek","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2025.05.010_bib82","article-title":"Developing ROR1 targeting CAR-T cells against solid tumors in preclinical studies","volume":"14","author":"Lee","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.hoc.2025.05.010_bib83","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1038\/s41591-020-1081-3","article-title":"Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial","volume":"26","author":"Shah","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.hoc.2025.05.010_bib84","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s40425-017-0246-1","article-title":"A tandem CD19\/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines","volume":"5","author":"Schneider","year":"2017","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.hoc.2025.05.010_bib85","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1158\/2326-6066.CIR-15-0231","article-title":"T cells expressing CD19\/CD20 bispecific chimeric antigen receptors prevent antigen escape by malignant b cells","volume":"4","author":"Zah","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.hoc.2025.05.010_bib86","first-page":"18","article-title":"Advancing CAR T-cell therapy for chronic lymphocytic leukemia: exploring resistance mechanisms and the innovative strategies to overcome them","volume":"7","author":"Borogovac","year":"2024","journal-title":"Cancer Drug Resist"},{"key":"10.1016\/j.hoc.2025.05.010_bib87","doi-asserted-by":"crossref","first-page":"4612","DOI":"10.1182\/blood-2022-162393","article-title":"Interleukin-18 secreting autologous anti-CD19 CAR T-cells (huCART19-IL18) in patients with non-Hodgkin lymphomas relapsed or refractory to prior CAR T-cell therapy","volume":"140","author":"Svoboda","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2025.05.010_bib88","doi-asserted-by":"crossref","first-page":"7004","DOI":"10.1200\/JCO.2024.42.16_suppl.7004","article-title":"Safety and efficacy of armored huCART19-IL18 in patients with relapsed\/refractory lymphomas that progressed after anti-CD19 CAR T cells","volume":"42","author":"Svoboda","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2025.05.010_bib89","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2015.64.5929","article-title":"Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease","volume":"34","author":"Brudno","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2025.05.010_bib90","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hoc.2025.05.010_bib91","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1182\/blood.2021011994","article-title":"Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities","volume":"141","author":"Falchi","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2025.05.010_bib92","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1182\/blood.2024025454","article-title":"Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after >\/=2 prior therapies","volume":"145","author":"Sehn","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2025.05.010_bib93","doi-asserted-by":"crossref","first-page":"e593","DOI":"10.1016\/S2352-3026(24)00166-2","article-title":"Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study","volume":"11","author":"Linton","year":"2024","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.hoc.2025.05.010_bib94","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large B-cell lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hoc.2025.05.010_bib95","doi-asserted-by":"crossref","first-page":"4089","DOI":"10.1182\/bloodadvances.2022009517","article-title":"Cytotoxicity of the CD3\u00d7CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting","volume":"7","author":"Mhibik","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.hoc.2025.05.010_bib96","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1182\/blood-2024-199708","article-title":"Epcoritamab monotherapy in patients (pts) with relapsed or refractory (R\/R) chronic lymphocytic leukemia (CLL): results from CLL expansion and optimization cohorts of Epcore CLL-1","volume":"144","author":"Danilov","year":"2024","journal-title":"Blood"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858825000826?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858825000826?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T04:50:15Z","timestamp":1760503815000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858825000826"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":97,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0889858825000826"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2025.05.010","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunotherapy in Chronic Lymphocytic Leukemia","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2025.05.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}